Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 27%
Hold 0%
Sell 9%
Strong Sell 0%

Bulls say

Glaukos is set to see strong revenue growth in the coming years, driven by the ramp up of sales for its iDose TR implant and the strong performance of its other micro-scale surgical device products. The company's expansion into new areas of the eye with products such as Epioxa and its iLution platform, as well as its strong progress on market access and expanding its provider network, should lead to continued profitability and potential upside in the stock's valuation. Overall, with a robust product pipeline and strong sales execution, Glaukos looks poised for success in the future and remains a Buy at this time.

Bears say

Glaukos is well-positioned to continue its strong growth trajectory, particularly with the launch and ramp of its iDose and Epioxa products. The company's robust pipeline and potential market expansions provide further growth opportunities. However, there are risks to be considered, such as competition in the MIGS market and potential reimbursement issues. Despite these potential challenges, we see long-term potential for Glaukos with a Buy rating and a price target of $136.

Glaukos (GKOS) has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 11 analysts, Glaukos (GKOS) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.